Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon

This article was originally published in The Pink Sheet Daily

Executive Summary

Biocon will manufacture biogeneric of Amgen’s Neupogen for Abraxis, the firm tells “The Pink Sheet” DAILY.

You may also be interested in...



Biocon Announces Partnership With U.S. Start-Up To Develop Novel Oncologic Drugs

India’s largest biotech teams with Baltimore’s IATRICa to develop immunoconjugates to fight cancers and infectious diseases.

Biocon Announces Partnership With U.S. Start-Up To Develop Novel Oncologic Drugs

India’s largest biotech teams with Baltimore’s IATRICa to develop immunoconjugates to fight cancers and infectious diseases.

Alpharma To Market Institut Biochimique’s Flector NSAID Patch In U.S.

Alpharma plans to double its in-house sales force from 200 to 400 reps, plus add 200 contract sales reps to market Flector.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel